Xvivo Perfusion AB (publ)
Xvivo Perfusion AB (publ) Fundamental Analysis
Xvivo Perfusion AB (publ) (XVIPF) shows weak financial fundamentals with a PE ratio of 90.48, profit margin of 8.86%, and ROE of 3.49%. The company generates $0.8B in annual revenue with weak year-over-year growth of -1.25%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 42.4/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze XVIPF's fundamental strength across five key dimensions:
Efficiency Score
WeakXVIPF struggles to generate sufficient returns from assets.
Valuation Score
ModerateXVIPF shows balanced valuation metrics.
Growth Score
WeakXVIPF faces weak or negative growth trends.
Financial Health Score
ExcellentXVIPF maintains a strong and stable balance sheet.
Profitability Score
WeakXVIPF struggles to sustain strong margins.
Key Financial Metrics
Is XVIPF Expensive or Cheap?
P/E Ratio
XVIPF trades at 90.48 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, XVIPF's PEG of -0.21 indicates potential undervaluation.
Price to Book
The market values Xvivo Perfusion AB (publ) at 3.08 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 51.72 times EBITDA. This signals the market has high growth expectations.
How Well Does XVIPF Make Money?
Net Profit Margin
For every $100 in sales, Xvivo Perfusion AB (publ) keeps $8.86 as profit after all expenses.
Operating Margin
Core operations generate 11.32 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.49 in profit for every $100 of shareholder equity.
ROA
Xvivo Perfusion AB (publ) generates $2.99 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Xvivo Perfusion AB (publ) produces operating cash flow of $181.30M, showing steady but balanced cash generation.
Free Cash Flow
Xvivo Perfusion AB (publ) produces free cash flow of $74.14M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $2.35 in free cash annually.
FCF Yield
XVIPF converts 1.11% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
90.48
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.21
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.08
vs 25 benchmark
P/S Ratio
Price to sales ratio
8.01
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.52
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.03
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.04
vs 25 benchmark
How XVIPF Stacks Against Its Sector Peers
| Metric | XVIPF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 90.48 | 29.24 | Worse (Expensive) |
| ROE | 3.49% | 713.00% | Weak |
| Net Margin | 8.86% | -42604.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.46 | Strong (Low Leverage) |
| Current Ratio | 4.52 | 4.36 | Strong Liquidity |
| ROA | 2.99% | -16668.00% (disorted) | Weak |
XVIPF outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Xvivo Perfusion AB (publ)'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
289.51%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
149.63%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
810.74%
Industry Style: Defensive, Growth, Innovation
High Growth